Journal of Clinical Pharmacy and Therapeutics
Overview
The Journal of Clinical Pharmacy and Therapeutics is a peer-reviewed publication dedicated to advancing the field of clinical pharmacy and therapeutics. It provides a platform for researchers, practitioners, and educators to share their latest findings, innovations, and insights in the areas of pharmacotherapy, medication management, and patient care. The journal covers a wide range of topics, including drug interactions, adverse drug reactions, clinical trials, and evidence-based practice, with the aim of improving patient outcomes and promoting safe and effective medication use.
Details
Details
Abbr.
J Clin Pharm Ther
Start
1987
End
Continuing
Frequency
Six no. a year
p-ISSN
0269-4727
e-ISSN
1365-2710
Country
United Kingdom
Language
English
Specialties
Pharmacology
Pharmacy
Pharmacy
Metrics
Metrics
h-index / Ranks: 4277
81
SJR / Ranks: 7933
569
CiteScore / Ranks: 8179
3.20
JIF / Ranks: 5186
2.0
Recent Articles
1.
Dong P, Pham V, Nguyen L, Le A, Nguyen T, Vu H, et al.
J Clin Pharm Ther
. 2022 Dec;
47(12):2107-2114.
PMID: 36543256
What Is Known And Objective: Unintentional medication discrepancies (UMDs) are common in geriatric patients during care transitions, resulting in frequent undesirable consequences. Medication reconciliation could be a useful practice to...
2.
Yilmaz M, Citirik M, Rahmanlar H, Alkan A, Gursoz H
J Clin Pharm Ther
. 2022 Dec;
47(12):2101-2106.
PMID: 36543255
What Is Known And Objective: Retinal vein occlusion (RVO) is one of the most common causes of vision loss. Anti-vascular endothelial growth factor (anti-VEGF) drugs, ranibizumab and aflibercept, and corticosteroid...
3.
Rahmani E, Lemelle T, Sharp H, Smarbafzadeh E, Kablinger A
J Clin Pharm Ther
. 2022 Dec;
47(12):2083-2090.
PMID: 36543254
What Is Known And Objective: Traumatic brain injury (TBI) is a major cause of disability, and it has been associated with agitation and aggression. In a previous study, we reviewed...
4.
Huang C, Hu C, Huang L, Chang E
J Clin Pharm Ther
. 2022 Dec;
47(12):2074-2082.
PMID: 36543253
What Is Known And Objective: Low treatment persistence and adherence in patients with dementia results in a rapid loss of disease control. This pilot study evaluated the impact of pharmacist-provided...
5.
Cao Y, Chi P, Zhou C, Lv W, Quan Z, Xue F
J Clin Pharm Ther
. 2022 Dec;
47(12):2068-2073.
PMID: 36543252
What Is Already Known And Objective: Sedation is routinely provided for patients undergoing gastrointestinal endoscopy. Remimazolam tosilate is a novel and short-acting sedative agent that has been used for sedation...
6.
Jiang Y, Zou Q, Zhang N, Chen J, Chen X, You Q, et al.
J Clin Pharm Ther
. 2022 Dec;
47(12):2320-2324.
PMID: 36511097
What Is Known And Objective: Immune disorder is a key trigger of recurrent spontaneous abortion (RSA); meanwhile, tumour necrosis factor inhibitor (TNFi) is a fundamental therapeutic for multiple immune and...
7.
Ciraldo K, Seraydarian M, Gasper J, DeFries T, Martin M
J Clin Pharm Ther
. 2022 Dec;
47(12):2393-2396.
PMID: 36511083
What Is Known And Objective: Individuals with medication adherence challenges or a preference for long-acting medications may benefit from extended-release naltrexone (XR-NTX) for treatment of alcohol use disorder (AUD). Individuals...
8.
Chen X, Sohouli M, Nateghi M, Melekoglu E, Fatahi S
J Clin Pharm Ther
. 2022 Dec;
47(12):1982-1993.
PMID: 36509962
Objective: The current study aimed to comprehensively evaluate the potential effects of mulberry consumption on cardiometabolic risk factors in adults. Methods: Relevant articles published up to January 2021 were systematically...
9.
Li C, Yu F, Xu W
J Clin Pharm Ther
. 2022 Dec;
47(12):2325-2334.
PMID: 36495117
What Is Known And Objective: Programmed cell death protein-1 (PD-1) inhibitors synergize apatinib for anti-tumour effect by regulating tumour microenvironment, vascular endothelial growth factor, hypoxia condition, immune response, etc. This...
10.
Qin X, Kong L, Wu C, Zhang X, Xie M, Wu X
J Clin Pharm Ther
. 2022 Dec;
47(12):2312-2319.
PMID: 36479719
What Is Known And Objective: To Investigate the pharmacokinetic/pharmacodynamic (PK/PD) parameters of high-dose tigecycline in plasma and sputum of patients with hospital-acquired pneumonia (HAP), and provide a therapeutic regimen of...